{"org_id": "T004443528", "org_name_cn": "苏州泽璟生物制药股份有限公司", "org_short_name_cn": "泽璟制药", "org_name_en": "Suzhou Zelgen Biopharmaceuticals Co.,Ltd.", "org_short_name_en": "Zelgen", "main_operation_business": "专注于肿瘤、出血及血液疾病、肝胆疾病和免疫炎症性疾病等多个治疗领域的创新驱动型化学及生物新药研发和生产。", "operating_scope": "　　从事新药的研究开发，相关的技术咨询、技术服务；从事制剂生产设备的制造；药品生产，销售自产产品（按相关许可证核定范围经营）。（国家限制类、禁止类除外）（依法须经批准的项目，经相关部门批准后方可开展经营活动）", "district_encode": "320583", "org_cn_introduction": "苏州泽璟生物制药股份有限公司的主营业务为专注于肿瘤、出血及血液疾病、肝胆疾病和免疫炎症性疾病等多个治疗领域的创新驱动型化学及生物新药研发和生产主要产品有多纳非尼、外用重组人凝血酶、盐酸杰克替尼片、盐酸杰克替尼乳膏、注射用重组人促甲状腺激素、奥卡替尼。", "legal_representative": "盛泽林", "general_manager": "盛泽林", "secretary": "高青平", "established_date": 1237305600000, "reg_asset": 240000000.0, "staff_num": 413, "telephone": "86-512-57018310", "postcode": "215300", "fax": "86-512-57018306", "email": "zelgen01@zelgen.com", "org_website": "www.zelgen.com", "reg_address_cn": "江苏省苏州市昆山市玉山镇晨丰路209号", "reg_address_en": "", "office_address_cn": "江苏省苏州市昆山市玉山镇晨丰路262号", "office_address_en": "", "currency_encode": "019001", "currency": "CNY", "listed_date": 1579708800000, "provincial_name": "江苏省", "actual_controller": "盛泽林 (20.73%)，陆惠萍 (5.86%)", "classi_name": "民营企业", "pre_name_cn": "苏州泽璟生物制药有限公司", "chairman": "盛泽林", "executives_nums": 16, "actual_issue_vol": 60000000.0, "issue_price": 33.76, "actual_rc_net_amt": 1908220799.9999998, "pe_after_issuing": null, "online_success_rate_of_issue": 0.05017704, "affiliate_industry": {"ind_code": "BK0040", "ind_name": "化学制药"}}